Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1903 1
1918 1
1942 1
1953 1
1954 1
1957 2
1959 1
1963 1
1970 1
1973 1
1974 2
1975 2
1976 1
1977 2
1978 6
1979 8
1980 7
1981 4
1982 7
1983 6
1984 6
1985 3
1986 5
1987 10
1988 1
1989 10
1990 12
1991 13
1992 13
1993 14
1994 10
1995 7
1996 5
1997 12
1998 12
1999 15
2000 13
2001 13
2002 14
2003 11
2004 19
2005 21
2006 33
2007 23
2008 27
2009 23
2010 15
2011 15
2012 19
2013 23
2014 25
2015 24
2016 23
2017 26
2018 23
2019 29
2020 41
2021 52
2022 43
2023 34
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

725 results

Results by year

Filters applied: . Clear all
Page 1
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Sehn LH, et al. Among authors: mcmillan a. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6. J Clin Oncol. 2020. PMID: 31693429 Free PMC article. Clinical Trial.
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, Kim TM, McMillan A, Ozcan M, Safar V, Salles G, Ku G, Hirata J, Chang YM, Musick L, Matasar MJ. Sehn LH, et al. Among authors: mcmillan a. Blood Adv. 2022 Jan 25;6(2):533-543. doi: 10.1182/bloodadvances.2021005794. Blood Adv. 2022. PMID: 34749395 Free PMC article. Clinical Trial.
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, Wu HT, Balcioglu M, Sethi H, Scott D, Foran J, McMillan A, Ford JM, Telli ML. Gruber JJ, et al. Among authors: mcmillan a. Nat Cancer. 2022 Oct;3(10):1181-1191. doi: 10.1038/s43018-022-00439-1. Epub 2022 Oct 17. Nat Cancer. 2022. PMID: 36253484 Free PMC article. Clinical Trial.
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, Besley C, Chaganti S, Sanderson R, O'Reilly M, Norman J, Osborne W, Bloor A, Lugthart S, Malladi R, Patten PEM, Neill L, Martinez-Cibrian N, Kennedy H, Phillips EH, Jones C, Sharplin K, El-Sharkawi D, Latif AL, Mathew A, Uttenthal B, Stewart O, Marzolini MAV, Townsend W, Cwynarski K, Ardeshna K, Ardavan A, Robinson K, Pagliuca A, Collins GP, Johnson R, McMillan A. Kuhnl A, et al. Among authors: mcmillan a. Br J Haematol. 2022 Aug;198(3):492-502. doi: 10.1111/bjh.18209. Epub 2022 Apr 29. Br J Haematol. 2022. PMID: 35485402
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.
Moorman AV, Barretta E, Butler ER, Ward EJ, Twentyman K, Kirkwood AA, Enshaei A, Schwab C, Creasey T, Leongamornlert D, Papaemmanuil E, Patrick P, Clifton-Hadley L, Patel B, Menne T, McMillan AK, Harrison CJ, Rowntree CJ, Marks DI, Fielding AK. Moorman AV, et al. Among authors: mcmillan ak. Leukemia. 2022 Mar;36(3):625-636. doi: 10.1038/s41375-021-01448-2. Epub 2021 Oct 16. Leukemia. 2022. PMID: 34657128 Free PMC article. Clinical Trial.
[68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity.
Rosenkrans ZT, Massey CF, Bernau K, Ferreira CA, Jeffery JJ, Schulte JJ, Moore M, Valla F, Batterton JM, Drake CR, McMillan AB, Sandbo N, Pirasteh A, Hernandez R. Rosenkrans ZT, et al. Among authors: mcmillan ab. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3705-3716. doi: 10.1007/s00259-022-05814-9. Epub 2022 May 12. Eur J Nucl Med Mol Imaging. 2022. PMID: 35556159 Free PMC article.
A new warhead in lymphoma therapy?
McMillan A. McMillan A. Blood. 2021 May 13;137(19):2568-2570. doi: 10.1182/blood.2020009782. Blood. 2021. PMID: 33983420 Free PMC article. No abstract available.
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.
Davies AJ, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, Mamot C, Novak U, McMillan A, Fields P, Collins GP, Stephens R, Cucco F, Sha C, van Hoppe M, Tooze R, Davies JR, Griffiths G, Schuh A, Burton C, Westhead DR, Du MQ, Johnson PWM. Davies AJ, et al. Among authors: mcmillan a. J Clin Oncol. 2023 May 20;41(15):2718-2723. doi: 10.1200/JCO.23.00033. Epub 2023 Mar 27. J Clin Oncol. 2023. PMID: 36972491 Free PMC article. Clinical Trial.
Antibody-drug conjugates for multiple myeloma.
McMillan A, Warcel D, Popat R. McMillan A, et al. Expert Opin Biol Ther. 2021 Jul;21(7):889-901. doi: 10.1080/14712598.2020.1802422. Epub 2020 Aug 12. Expert Opin Biol Ther. 2021. PMID: 32729730 Review.
725 results